The clinical use of bone resorption markers in patients with malignant bone disease

Cancer

Volumn 94, Issue 10, 2002, Pages 2521-2533

  Coleman, Robert E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Bisphosphonate; Bone metabolism; Bone metastases; Bone resorption markers; Pamidronate; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

AMINO ACID URINE LEVEL; ARTICLE; BONE METABOLISM; BONE METASTASIS; CALCIUM URINE LEVEL; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DRUG EFFECT; HUMAN; OSTEOCLAST; OSTEOLYSIS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; BONE NEOPLASMS; BONE RESORPTION; DIPHOSPHONATES; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037093808     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10522     Document Type: Article

References (77)

1. The clinical course of bone metastases from breast cancer
2. Skeletal complications of malignancy
3. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials
4. Bone metastases in breast cancer patients
5. Assessment of bone involvement in patients with multiple myeloma using bone densitometry
6. Bone densitometry in patients with multiple myeloma
7. The systemic treatment of bone metastases
8. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
9. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
10. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lyric bone metastases
11. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
12. Metabolic effects of pamidronate in patients with metastatic bone disease
13. Bisphosphonates as anticancer drugs
14. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
15. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer
16. Bone scan flare predicts successful systemic therapy for bone metastases
17. Comparison of magnetic resonance imaging and radionuclide bone scan in the evaluation of primary and metastatic disease to the bone
18. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography
19. Effects of bone metastases on bone metabolism: Implications for diagnosis, imaging and assessment of response to cancer treatment
20. Assessment of response to treatment
21. Biochemical prediction of response of bone metastases to treatment
22. Novel serum markers of bone resorption: Clinical assessment and comparison with established urinary indices
23. Markers of bone resorption in patients treated with pamidronate
24. Bone markers in clinical practice
25. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease
26. Diagnostic validity of bone metabolic markers for bone metastasis
27. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors
28. (Pro)collagenase (matrix metalloproteinase-1) is present in rodent osteoclasts and in the underlying bone-resorbing compartment
29. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts
30. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification
31. Relation between serum and urinary calcium with particular reference to parathyroid activity
32. Calcium excretion (CaE) in metastatic breast cancer
33. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease
34. Estimation of whole body bone resorption rate: A comparison of urinary total hydroxyproline excretion with two radioisotopic tracer methods in osteoporosis
35. The clinical measurement of urinary total hydroxyproline excretion
36. Circadian rhythm of urinary total and free hydroxyproline excretion and its relation to creatinine excretion
37. Total urinary and free serum hydroxyproline in metastatic bone disease
38. The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy, and biochemical markers of bone metabolism
39. Intravenous pamidronate in patients with tumor-induced osteolysis: A biochemical dose-response study
40. Assessment of response of bone metastases to systemic treatment in patients with breast cancer
41. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study
42. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases
43. Immunoassay for quantifying type I collagen degradation products in urine evaluated
44. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine
45. Urinary pyridinium crosslinks of collagen: Specific markers of bone resorption in metabolic bone disease
46. Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases
47. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption
48. Urinary collagen crosslinks are highly correlated with radioisotopic measurements of bone resorption
49. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis
50. Biochemical markers of bone turnover in patients with metastatic bone disease
51. Comparative evaluation of markers of bone resorption after a single dose of pamidronate in patients with breast cancer induced osteolysis
52. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease
53. Effect of bisphosphonate therapies (pamidronate and ibandronate) on the excretion of degradation products of the C-telopeptides of type I collagen measured by a radioimmunoassay (Crosslaps™ RIA)
54. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy
55. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy
56. Assessment of bone response to systemic therapy in an EORTC trial: Preliminary experience with the use of collagen cross-link excretion
57. Clinical studies using measurements of N-telopeptides of type I collagen (NTx) in patients with bone metastases. Comparison with bone scintigraphy and other metabolic markers
58. Biochemical markers of bone metabolism: An overview
59. Clinical utility of biochemical markers of bone remodeling
60. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer
61. Bone sialoprotein in serum of patients with malignant bone diseases
62. Ectopic expression of bone sialoprotein in human thyroid cancer
63. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development
64. Expression of bone sialoprotein in primary human breast cancer is associated with poor survival
65. Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay
66. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer
67. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: A prospective study
68. Markers of bone turnover for the management of patients with bone metastases from prostate cancer
69. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone
70. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: Diagnostic efficacy and the effect of hormonal therapy
71. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis
72. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer
73. Markers of bone turnover in prostate cancer
74. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton
75. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases
76. A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease
77. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases